| 7 April, 2005 |
 |
| Olympus and AntiCancer, Inc.,
Form Technology Partnership |
| for Small Animal Molecular
Imaging |
|
|
 |
| Olympus Corporation (Olympus, President: Tsuyoshi Kikukawa)
has formed a technology partnership with AntiCancer Inc. (CEO: Dr.
Robert M. Hoffman, headquarters: San Diego, California, U.S.A.). Starting
in April 2005, the two companies will conduct joint research, applying
AntiCancer's proprietary fluorescent-protein-based small-animal imaging
technology to a highly sensitive fluorescence molecular imaging system
developed by Olympus. |
|
| Olympus will display its in vivo molecular imaging
system and micro laser scanning microscope in its booth at the annual
meeting of the American Association for Cancer Research (President.
Lynn M. Matrisian, Ph.D.), to be held in Anaheim, California, April
16-20, 2005. |
|
| Background |
|
| Molecular
imaging enables visualization of cellular and molecular events within
a living body and is an important tool for understanding the mechanisms
of disease. Molecular imaging is being increasingly used in cancer
and other biomedical research. Molecular imaging plays an important
role in translational research which develops clinical applications
from basic research. |
|
| Olympus
is targeting translational research with the development of its in
vivo macro and micro fluorescence imaging system for small animals
as well as a micro laser scanning microscope designed for small animals.
AntiCancer is the leading developer of imageable small animal models
of metastasis. The Olympus-AntiCancer partnership will begin in April
by joining AntiCancer’s fluorescent metastasis mouse models
and Olympus’ optical technology to develop new applications
for translational cancer research. The combination of Olympus optical
technology with AntiCancer’s fluorescent-protein-based imageable
animal models enables multi-color whole-body macro-imaging and intravital
cellular and subcellular imaging of cancer and other processes in
live animals. The Olympus-AntiCancer partnership will develop numerous
translational-research applications for drug discovery and evaluation,
as well as basic research. |
|
| Overview of AntiCancer Inc. |
|
| Address: |
|
7917 Ostrow Street. San Diego CA 92111, USA |
| CEO: |
Dr. Robert M. Hoffman |
| Founded: |
1984 |
| About AntiCancer: |
AntiCancer, founded in 1984 and based in San Diego has developed
the leading mouse models of cancer including MetaMouse®
and AngioMouse®. These models are made imageable with AntiCancer’s
OncoBrite® technology using fluorescent proteins. AntiCancer
is also developing new cancer drugs based on genetic engineering
that target cancer-specific metabolic defects. The company is
also developing recombinant-enzyme-based diagnostics for cancer
and cardiovascular disease. AntiCancer also offers the Histoculture
Drug Response Assay (HDRA) for individualized cancer treatment.
AntiCancer pioneered hair follicle gene therapy and is also
pioneering the use of pluripotent hair-follicle stem cells for
chemotherapy-induced hair loss and regenerative medicine for
neurological and other diseases. |
| URL: |
|
http://www.anticancer.com/ |
|
|
 |
*The company names and product names specified in this release are the trademarks or registered trademarks of each company.
Please be advised that press releases and information posted on this site are current at the time of the original publication date. Please note that they may now be outdated or rendered inaccurate.
Contents end
